corp_html/news/37.html

<p align="center"><b>PLIVA's Scientists - Heroes of Chemistry</b> </p>
<p>The "Heroes of Chemistry 2000"ceremony was held on 20 August 2000 in Washington 
  D.C., USA, organised by the American Chemical Society (ACS), a non-profit association 
  of American chemists and chemical engineers and the largest association of scientists 
  in the world. For the discovery of azithromycin, the first class of azalide 
  antibiotics, PLIVA scientists Dr. Slobodan Dokic and Gabrijela Kobrehel, M.Sc., 
  were named heroes of chemistry, together with representatives from US-based 
  Pfizer which had also contributed to the success of Sumamed and Zithromax. On 
  behalf of the late Dr. Dokic, his widow Lidija and son, Dr. Darije Dokic, attended 
  the presentation ceremony.</p>
<p> The "Heroes of Chemistry 2000" award is one of numerous awards presented over 
  the years to PLIVA scientists for their long-term contribution to global science, 
  medicine and the improvement of quality of life. This latest recognition is 
  additional confirmation of the value and achievements of PLIVA's entire team 
  of researchers who worked on the discovery of azithromycin, which apart from 
  Dr. Slobodan Dokic and Gabrijela Kobrehel, M.Sc., also included Dr. Zrinka Tamburasev 
  and Gorjana Radobolja-Lazarevski, M.Sc.. </p>
<p>The discovery of azithromycin was the greatest event in PLIVA's history and 
  a milestone for the Croatian pharmaceuticals industry. As a result of consistent 
  efforts and dedication to research, in 1980 PLIVA scientists discovered and 
  patented a new original macrolide antibiotic called azithromycin. Because of 
  its exceptional therapeutic properties, azithromycin, sold by PLIVA under the 
  brand name Sumamed, revolutionised antibiotic treatment and became one of the 
  most successful drugs world-wide. Its success has put PLIVA among the few pharmaceutical 
  companies in the world that have developed their own drug and has listed Croatia 
  among only nine countries world-wide that have their own antibiotic substance. 
</p>
<p>At the 220th national ACS meeting, which was dedicated to celebrating the innovators 
  from the field of chemistry who have contributed to improving the human condition 
  on a world-wide scale, six individuals and six teams of scientists were named 
  heroes of chemistry. The awarded scientists came from 10 pharmaceutical companies 
  from across the world, including giants such as BASF, Bristol-Myers, Squibb, 
  Novartis, Dow Chemicals, Procter & Gamble and Xerox. </p>
<p>"Selecting Dr. Slobodan Dokic and Gabrijela Kobrehel, M.Sc., as heroes of chemistry 
  is truly great recognition from the Association of American Chemists and Chemical 
  Engineers of their achievements and their dedicated scientific work and research 
  throughout the years together with PLIVA's team of scientists who participated 
  in this great discovery. I also believe it is a confirmation of how important 
  it is for PLIVA to further focus on research and new drug discovery. This will 
  lead to new PLIVA products that will, as it did with azithromycin, bring advancements 
  to drug treatment and contribute to global science," said Dr. Radan Spaventi, 
  PLIVA's Chief Scientific Officer. </p>
1	dpavlin	1.1	<p align="center"><b>PLIVA's Scientists - Heroes of Chemistry</b> </p>
2			<p>The "Heroes of Chemistry 2000"ceremony was held on 20 August 2000 in Washington
3			D.C., USA, organised by the American Chemical Society (ACS), a non-profit association
4			of American chemists and chemical engineers and the largest association of scientists
5			in the world. For the discovery of azithromycin, the first class of azalide
6			antibiotics, PLIVA scientists Dr. Slobodan Dokic and Gabrijela Kobrehel, M.Sc.,
7			were named heroes of chemistry, together with representatives from US-based
8			Pfizer which had also contributed to the success of Sumamed and Zithromax. On
9			behalf of the late Dr. Dokic, his widow Lidija and son, Dr. Darije Dokic, attended
10			the presentation ceremony.</p>
11			<p> The "Heroes of Chemistry 2000" award is one of numerous awards presented over
12			the years to PLIVA scientists for their long-term contribution to global science,
13			medicine and the improvement of quality of life. This latest recognition is
14			additional confirmation of the value and achievements of PLIVA's entire team
15			of researchers who worked on the discovery of azithromycin, which apart from
16			Dr. Slobodan Dokic and Gabrijela Kobrehel, M.Sc., also included Dr. Zrinka Tamburasev
17			and Gorjana Radobolja-Lazarevski, M.Sc.. </p>
18			<p>The discovery of azithromycin was the greatest event in PLIVA's history and
19			a milestone for the Croatian pharmaceuticals industry. As a result of consistent
20			efforts and dedication to research, in 1980 PLIVA scientists discovered and
21			patented a new original macrolide antibiotic called azithromycin. Because of
22			its exceptional therapeutic properties, azithromycin, sold by PLIVA under the
23			brand name Sumamed, revolutionised antibiotic treatment and became one of the
24			most successful drugs world-wide. Its success has put PLIVA among the few pharmaceutical
25			companies in the world that have developed their own drug and has listed Croatia
26			among only nine countries world-wide that have their own antibiotic substance.
27			</p>
28			<p>At the 220th national ACS meeting, which was dedicated to celebrating the innovators
29			from the field of chemistry who have contributed to improving the human condition
30			on a world-wide scale, six individuals and six teams of scientists were named
31			heroes of chemistry. The awarded scientists came from 10 pharmaceutical companies
32			from across the world, including giants such as BASF, Bristol-Myers, Squibb,
33			Novartis, Dow Chemicals, Procter & Gamble and Xerox. </p>
34			<p>"Selecting Dr. Slobodan Dokic and Gabrijela Kobrehel, M.Sc., as heroes of chemistry
35			is truly great recognition from the Association of American Chemists and Chemical
36			Engineers of their achievements and their dedicated scientific work and research
37			throughout the years together with PLIVA's team of scientists who participated
38			in this great discovery. I also believe it is a confirmation of how important
39			it is for PLIVA to further focus on research and new drug discovery. This will
40			lead to new PLIVA products that will, as it did with azithromycin, bring advancements
41			to drug treatment and contribute to global science," said Dr. Radan Spaventi,
42			PLIVA's Chief Scientific Officer. </p>